<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39460316</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Symptomatology and IgG Levels before and after SARS-CoV-2 Omicron Breakthrough Infections in Vaccinated Individuals.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1149</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12101149</ELocationID><Abstract><AbstractText>(1) Background: After the COVID-19 pandemic, there is concern regarding the immunity of the population to SARS-CoV-2 variants, particularly the Omicron variant and its sub-lineages. (2) Methods: The study involved analyzing the immune response and symptomatology of 27 vaccinated individuals who were subsequently infected by Omicron sub-lineages. Blood samples were collected for serological analysis, including the detection of IgG antibodies reactive to the Nucleocapsid (N) and Spike (S) antigens of SARS-CoV-2. Additionally, participants were interviewed to assess the intensity of symptoms during the infection. (3) Results: Despite the high levels of anti-Spike IgG observed after vaccination, all participants were infected by Omicron sub-lineages. The most common symptoms reported by participants were fever or chills, sore throat, and cough. The levels of anti-Spike IgG found prior to infection did not correlate with symptom intensity post-infection. However, it was observed that high post-infection anti-Nucleocapsid IgG levels correlated with mild symptoms during the course of the disease, suggesting a potential role for anti-N antibodies in symptom intensity. (4) Conclusions: In line with previous studies, the high levels of IgG anti-Spike resulting from vaccination did not provide complete protection against infection by the Omicron variant. Additionally, our data suggest that anti-Nucleocapsid IgG titers are negatively correlated with the intensity of the symptoms during mild infections.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paula</LastName><ForeName>Nigella M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Setor Litoral, Federal University of Paraná-UFPR, Matinhos 83260-00, PR, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduated Program in Sciences-Biochemistry, Federal University of Paraná-UFPR, Curitiba 81530-00, PR, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joucoski</LastName><ForeName>Emerson</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-7339-9476</Identifier><AffiliationInfo><Affiliation>Setor Litoral, Federal University of Paraná-UFPR, Matinhos 83260-00, PR, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baura</LastName><ForeName>Valter A</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Graduated Program in Sciences-Biochemistry, Federal University of Paraná-UFPR, Curitiba 81530-00, PR, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Souza</LastName><ForeName>Emanuel M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Graduated Program in Sciences-Biochemistry, Federal University of Paraná-UFPR, Curitiba 81530-00, PR, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedrosa</LastName><ForeName>Fabio O</ForeName><Initials>FO</Initials><Identifier Source="ORCID">0000-0003-3711-969X</Identifier><AffiliationInfo><Affiliation>Graduated Program in Sciences-Biochemistry, Federal University of Paraná-UFPR, Curitiba 81530-00, PR, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonçalves</LastName><ForeName>Alan G</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0000-0001-8459-3437</Identifier><AffiliationInfo><Affiliation>Setor Litoral, Federal University of Paraná-UFPR, Matinhos 83260-00, PR, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduated Program in Farmacy-Biochemistry, Federal University of Paraná-UFPR, Curitiba 81530-00, PR, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huergo</LastName><ForeName>Luciano F</ForeName><Initials>LF</Initials><Identifier Source="ORCID">0000-0002-7587-9510</Identifier><AffiliationInfo><Affiliation>Setor Litoral, Federal University of Paraná-UFPR, Matinhos 83260-00, PR, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduated Program in Sciences-Biochemistry, Federal University of Paraná-UFPR, Curitiba 81530-00, PR, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">IgG</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">omicron</Keyword><Keyword MajorTopicYN="N">symptoms</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460316</ArticleId><ArticleId IdType="pmc">PMC11512233</ArticleId><ArticleId IdType="doi">10.3390/vaccines12101149</ArticleId><ArticleId IdType="pii">vaccines12101149</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Iheanacho C.O., Eze U.I.H., Adida E.A. A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population. Bull. Natl. Res. Cent. 2021;45:150. doi: 10.1186/s42269-021-00607-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s42269-021-00607-w</ArticleId><ArticleId IdType="pmc">PMC8383253</ArticleId><ArticleId IdType="pubmed">34456555</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerqueira-Silva T., Andrews J.R., Boaventura V.S., Ranzani O.T., Oliveira V.D.A., Paixão E.S., Júnior J.B., Machado T.M., Hitchings M.D.T., Dorion M., et al. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: A test-negative, case-control study. Lancet Infect. Dis. 2022;22:791–801. doi: 10.1016/S1473-3099(22)00140-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00140-2</ArticleId><ArticleId IdType="pmc">PMC8971277</ArticleId><ArticleId IdType="pubmed">35366959</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerqueira-Silva T., Katikireddi S.V., Oliveira V.d.A., Flores-Ortiz R., Júnior J.B., Paixão E.S., Robertson C., Penna G.O., Werneck G.L., Barreto M.L., et al. Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil. Nat. Med. 2022;28:838–843. doi: 10.1038/s41591-022-01701-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01701-w</ArticleId><ArticleId IdType="pmc">PMC9018414</ArticleId><ArticleId IdType="pubmed">35140406</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadlyana E., Setiabudi D., Kartasasmita C.B., Putri N.D., Hadinegoro S.R., Mulholland K., Sofiatin Y., Suryadinata H., Hartantri Y., Sukandar H., et al. Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: A randomised, observer-masked, controlled trial in Indonesia. Lancet Infect. Dis. 2023;23:545–555. doi: 10.1016/S1473-3099(22)00800-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00800-3</ArticleId><ArticleId IdType="pubmed">36640798</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. doi: 10.1016/S0140-6736(20)32661-1. Erratum in Lancet 2021, 397, 98.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32661-1</ArticleId><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn R., Janusz C.B., Castro M.C., Matos A.d.R., Domingues C., Ponmattam J., Rey-Benito G., Toscano C.M., de Oliveira L.H., Rearte A., et al. The effectiveness of COVID-19 vaccines in Latin America, 2021: A multicenter regional case-control study. Lancet Reg. Health Am. 2023;20:100474. doi: 10.1016/j.lana.2023.100474.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2023.100474</ArticleId><ArticleId IdType="pmc">PMC10049854</ArticleId><ArticleId IdType="pubmed">37008741</ArticleId></ArticleIdList></Reference><Reference><Citation>dos Santos C.V.B., Valiati N.C.M., de Noronha T.G., Porto V.B.G., Pacheco A.G., Freitas L.P., Coelho F.C., Gomes M.F.d.C., Bastos L.S., Cruz O.G., et al. The effectiveness of COVID-19 vaccines against severe cases and deaths in Brazil from 2021 to 2022: A registry-based study. Lancet Reg. Health Am. 2023;20:100465. doi: 10.1016/j.lana.2023.100465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2023.100465</ArticleId><ArticleId IdType="pmc">PMC10010656</ArticleId><ArticleId IdType="pubmed">36936517</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravichandran S., Lee Y., Grubbs G., Coyle E.M., Klenow L., Akasaka O., Koga M., Adachi E., Saito M., Nakachi I., et al. Longitudinal antibody repertoire in “mild” versus “severe” COVID-19 patients reveals immune markers associated with disease severity and resolution. Sci. Adv. 2021;7:eabf2467. doi: 10.1126/sciadv.abf2467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abf2467</ArticleId><ArticleId IdType="pmc">PMC7935365</ArticleId><ArticleId IdType="pubmed">33674317</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J., Liang B.-Y., Fang Y.-H., Wang H., Yang X.-L., Shen S., Chen L.-K., Li S.-M., Lu S.-H., Xiang T.-D., et al. Occurrence of COVID-19 Symptoms During SARS-CoV-2 Infection Defines Waning of Humoral Immunity. Front. Immunol. 2021;12:722027. doi: 10.3389/fimmu.2021.722027.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.722027</ArticleId><ArticleId IdType="pmc">PMC8416539</ArticleId><ArticleId IdType="pubmed">34489971</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajilooi M., Keramat F., Moazenian A., Rastegari-Pouyani M., Solgi G. The quantity and quality of anti-SARS-CoV-2 antibodies show contrariwise association with COVID-19 severity: Lessons learned from IgG avidity. Med. Microbiol. Immunol. 2023;212:203–220. doi: 10.1007/s00430-023-00763-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00430-023-00763-y</ArticleId><ArticleId IdType="pmc">PMC10133916</ArticleId><ArticleId IdType="pubmed">37103583</ArticleId></ArticleIdList></Reference><Reference><Citation>Paula N.M., Conzentino M.S., Gonçalves A.C.A., da Silva R., Weissheimer K.V., Kluge C.H.S., Marins P.H.S.A., Camargo H.S.C., Farias L.R.P., Sant’ana T.P., et al. Population-Based Analysis of the Immunoglobulin G Response to Different COVID-19 Vaccines in Brazil. Vaccines. 2023;11:21. doi: 10.3390/vaccines11010021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11010021</ArticleId><ArticleId IdType="pmc">PMC9862407</ArticleId><ArticleId IdType="pubmed">36679871</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreira E.D., Kitchin N., Xu X., Dychter S.S., Lockhart S., Gurtman A., Perez J.L., Zerbini C., Dever M.E., Jennings T.W., et al. Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. N. Engl. J. Med. 2022;386:1910–1921. doi: 10.1056/NEJMoa2200674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2200674</ArticleId><ArticleId IdType="pmc">PMC9006787</ArticleId><ArticleId IdType="pubmed">35320659</ArticleId></ArticleIdList></Reference><Reference><Citation>Barin B., Kasap U., Selçuk F., Volkan E., Uluçkan Ö. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: A prospective, longitudinal population-based study. Lancet Microbe. 2022;3:e274–e283. doi: 10.1016/S2666-5247(21)00305-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00305-0</ArticleId><ArticleId IdType="pmc">PMC8828370</ArticleId><ArticleId IdType="pubmed">35165669</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratesi F., Caruso T., Testa D., Tarpanelli T., Gentili A., Gioè D., Migliorini P. BNT162b2 mRNA SARS-CoV-2 Vaccine Elicits High Avidity and Neutralizing Antibodies in Healthcare Workers. Vaccines. 2021;9:672. doi: 10.3390/vaccines9060672.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9060672</ArticleId><ArticleId IdType="pmc">PMC8234791</ArticleId><ArticleId IdType="pubmed">34207300</ArticleId></ArticleIdList></Reference><Reference><Citation>Feikin D.R., Feikin D.R., Higdon M.M., Higdon M.M., Abu-Raddad L.J., Abu-Raddad L.J., Andrews N., Andrews N., Araos R., Araos R., et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: Results of a systematic review and meta-regression. Lancet. 2022;399:924–944. doi: 10.1016/S0140-6736(22)00152-0. Erratum in Lancet 2023, 401, 644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00152-0</ArticleId><ArticleId IdType="pmc">PMC8863502</ArticleId><ArticleId IdType="pubmed">35202601</ArticleId></ArticleIdList></Reference><Reference><Citation>Ssentongo P., Ssentongo A.E., Voleti N., Groff D., Sun A., Ba D.M., Nunez J., Parent L.J., Chinchilli V.M., Paules C.I. SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: A systematic review and meta-analysis. BMC Infect. Dis. 2022;22:439. doi: 10.1186/s12879-022-07418-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07418-y</ArticleId><ArticleId IdType="pmc">PMC9077344</ArticleId><ArticleId IdType="pubmed">35525973</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrotri M., Navaratnam A.M.D., Nguyen V., Byrne T., Geismar C., Fragaszy E., Beale S., Fong W.L.E., Patel P., Kovar J., et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet. 2021;398:385–387. doi: 10.1016/S0140-6736(21)01642-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01642-1</ArticleId><ArticleId IdType="pmc">PMC8285117</ArticleId><ArticleId IdType="pubmed">34274038</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin E.G., Lustig Y., Cohen C., Fluss R., Indenbaum V., Amit S., Doolman R., Asraf K., Mendelson E., Ziv A., et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N. Engl. J. Med. 2021;385:e84. doi: 10.1056/NEJMoa2114583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114583</ArticleId><ArticleId IdType="pmc">PMC8522797</ArticleId><ArticleId IdType="pubmed">34614326</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Y., Wang W., Ma J., Wu S., Sun F. Reinfection rates among patients previously infected by SARS-CoV-2: Systematic review and meta-analysis. Chin. Med. J. 2022;135:145–152. doi: 10.1097/CM9.0000000000001892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000001892</ArticleId><ArticleId IdType="pmc">PMC8769121</ArticleId><ArticleId IdType="pubmed">34908003</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen C.H., Michlmayr D., Gubbels S.M., Mølbak K., Ethelberg S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: A population-level observational study. Lancet. 2021;397:1204–1212. doi: 10.1016/S0140-6736(21)00575-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00575-4</ArticleId><ArticleId IdType="pmc">PMC7969130</ArticleId><ArticleId IdType="pubmed">33743221</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordström P., Ballin M., Nordström A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: A retrospective, total population cohort study in Sweden. Lancet Infect Dis. 2022;22:781–790. doi: 10.1016/S1473-3099(22)00143-8. Erratum in Lancet Infect Dis. 2022, 22, E159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00143-8</ArticleId><ArticleId IdType="pmc">PMC8971363</ArticleId><ArticleId IdType="pubmed">35366962</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Nagelkerke N., Ayoub H.H., Coyle P., Tang P., Yassine H.M., A Al-Khatib H., Smatti M.K., Hasan M.R., Al-Kanaani Z., et al. Duration of immune protection of SARS-CoV-2 natural infection against reinfection. J. Travel. Med. 2022;29:taac109. doi: 10.1093/jtm/taac109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jtm/taac109</ArticleId><ArticleId IdType="pmc">PMC9619565</ArticleId><ArticleId IdType="pubmed">36179099</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt F., Weisblum Y., Rutkowska M., Poston D., DaSilva J., Zhang F., Bednarski E., Cho A., Schaefer-Babajew D.J., Gaebler C., et al. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. Nature. 2021;600:512–516. doi: 10.1038/s41586-021-04005-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04005-0</ArticleId><ArticleId IdType="pmc">PMC9241107</ArticleId><ArticleId IdType="pubmed">34544114</ArticleId></ArticleIdList></Reference><Reference><Citation>Wratil P.R., Stern M., Priller A., Willmann A., Almanzar G., Vogel E., Feuerherd M., Cheng C.-C., Yazici S., Christa C., et al. Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. Nat. Med. 2022;28:496–503. doi: 10.1038/s41591-022-01715-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01715-4</ArticleId><ArticleId IdType="pubmed">35090165</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews N., Stowe J., Kirsebom F., Toffa S., Rickeard T., Gallagher E., Gower C., Kall M., Groves N., O’Connell A.M., et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N. Engl. J. Med. 2022;386:1532–1546. doi: 10.1056/NEJMoa2119451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2119451</ArticleId><ArticleId IdType="pmc">PMC8908811</ArticleId><ArticleId IdType="pubmed">35249272</ArticleId></ArticleIdList></Reference><Reference><Citation>Altarawneh H.N., Chemaitelly H., Ayoub H.H., Tang P., Hasan M.R., Yassine H.M., Al-Khatib H.A., Smatti M.K., Coyle P., Al-Kanaani Z., et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. N. Engl. J. Med. 2022;387:21–34. doi: 10.1056/NEJMoa2203965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2203965</ArticleId><ArticleId IdType="pmc">PMC9258753</ArticleId><ArticleId IdType="pubmed">35704396</ArticleId></ArticleIdList></Reference><Reference><Citation>Freire-Neto F.P., Teixeira D.G., da Cunha D.C.S., Morais I.C., Tavares C.P.M., Gurgel G.P., Medeiros S.D.N., dos Santos D.C., Sales A.D.O., Jeronimo S.M.B. SARS-CoV-2 reinfections with BA.1 (Omicron) variant among fully vaccinated individuals in northeastern Brazil. PLoS Negl. Trop. Dis. 2022;16:e0010337. doi: 10.1371/journal.pntd.0010337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0010337</ArticleId><ArticleId IdType="pmc">PMC9560550</ArticleId><ArticleId IdType="pubmed">36191040</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira J.R., Ruiz C.M.R., Machado R.R.G., Magawa J.Y., Daher I.P., Urbanski A.H., Schmitz G.J.H., Arcuri H.A., Ferreira M.A., Sasahara G.L., et al. Immunodominant antibody responses directed to SARS-CoV-2 hotspot mutation sites and risk of immune escape. Front. Immunol. 2023;13:1010105. doi: 10.3389/fimmu.2022.1010105.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1010105</ArticleId><ArticleId IdType="pmc">PMC9849925</ArticleId><ArticleId IdType="pubmed">36685521</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhoden J., Hoffmann A.T., Stein J.F., da Silva M.S., Gularte J.S., Filippi M., Demoliner M., Girardi V., Spilki F.R., Fleck J.D., et al. Diversity of Omicron sublineages and clinical characteristics in hospitalized patients in the southernmost state of Brazil. BMC Infect. Dis. 2024;24:193. doi: 10.1186/s12879-024-09089-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-024-09089-3</ArticleId><ArticleId IdType="pmc">PMC10863127</ArticleId><ArticleId IdType="pubmed">38350887</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette A., Crotty S. Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines. Immunol. Rev. 2022;310:27–46. doi: 10.1111/imr.13089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.13089</ArticleId><ArticleId IdType="pmc">PMC9349657</ArticleId><ArticleId IdType="pubmed">35733376</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel R.R., Apostolidis S.A., Painter M.M., Mathew D., Pattekar A., Kuthuru O., Gouma S., Hicks P., Meng W., Rosenfeld A.M., et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. Sci. Immunol. 2021;6:eabi6950. doi: 10.1126/sciimmunol.abi6950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abi6950</ArticleId><ArticleId IdType="pmc">PMC8158969</ArticleId><ArticleId IdType="pubmed">33858945</ArticleId></ArticleIdList></Reference><Reference><Citation>Otto S.P., Day T., Arino J., Colijn C., Dushoff J., Li M., Mechai S., Van Domselaar G., Wu J., Earn D.J., et al. The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic. Curr. Biol. 2021;31:R918–R929. doi: 10.1016/j.cub.2021.06.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2021.06.049</ArticleId><ArticleId IdType="pmc">PMC8220957</ArticleId><ArticleId IdType="pubmed">34314723</ArticleId></ArticleIdList></Reference><Reference><Citation>Calistri P., Amato L., Puglia I., Cito F., Di Giuseppe A., Danzetta M.L., Morelli D., Di Domenico M., Caporale M., Scialabba S., et al. Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by longer persistence and higher viral RNA loads in nasopharyngeal swabs. Int. J. Infect. Dis. 2021;105:753–755. doi: 10.1016/j.ijid.2021.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.03.005</ArticleId><ArticleId IdType="pmc">PMC7934691</ArticleId><ArticleId IdType="pubmed">33684558</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D., Zhong J., Xiong H., Li Y., Guo T., Peng B., Fang C., Kang Y., Tan J., Ma Y. Protective Effect of Inactivated COVID-19 Vaccines against Omicron BA.2 Infection in Guangzhou: A Test-Negative Case-Control Real-World Study. Vaccines. 2023;11:566. doi: 10.3390/vaccines11030566.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11030566</ArticleId><ArticleId IdType="pmc">PMC10053421</ArticleId><ArticleId IdType="pubmed">36992150</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrett N., Tapley A., Andriesen J., Seocharan I., Fisher L.H., Bunts L., Espy N., Wallis C.L., Randhawa A.K., Ketter N., et al. High Rate of Asymptomatic Carriage Associated with Variant Strain Omicron. medRxiv. 2022 doi: 10.1101/2021.12.20.21268130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.20.21268130</ArticleId></ArticleIdList></Reference><Reference><Citation>Carabelli A.M., Peacock T.P., Thorne L.G., Harvey W.T., Hughes J., Peacock S.J., Barclay W.S., de Silva T.I., Towers G.J., COVID-19 Genomics UK Consortium et al. SARS-CoV-2 variant biology: Immune escape, transmission and fitness. Nat. Rev. Microbiol. 2023;21:162–177. doi: 10.1038/s41579-022-00841-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00841-7</ArticleId><ArticleId IdType="pmc">PMC9847462</ArticleId><ArticleId IdType="pubmed">36653446</ArticleId></ArticleIdList></Reference><Reference><Citation>Markov P.V., Ghafari M., Beer M., Lythgoe K., Simmonds P., Stilianakis N.I., Katzourakis A. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 2023;21:361–379. doi: 10.1038/s41579-023-00878-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-023-00878-2</ArticleId><ArticleId IdType="pubmed">37020110</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuekprakhon A., Nutalai R., Dijokaite-Guraliuc A., Zhou D., Ginn H.M., Selvaraj M., Liu C., Mentzer A.J., Supasa P., Duyvesteyn H.M., et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 2022;185:2422–2433.e13. doi: 10.1016/j.cell.2022.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.06.005</ArticleId><ArticleId IdType="pmc">PMC9181312</ArticleId><ArticleId IdType="pubmed">35772405</ArticleId></ArticleIdList></Reference><Reference><Citation>Huergo L.F., Paula N.M., Gonçalves A.C.A., Kluge C.H.S., Marins P.H.S.A., Camargo H.S.C., Sant’ana T.P., Farias L.R.P., Aldrighi J.D., Lima S., et al. SARS-CoV-2 Seroconversion in Response to Infection and Vaccination: A Time Series Local Study in Brazil. Microbiol. Spectr. 2022;10:e01026-22. doi: 10.1128/spectrum.01026-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.01026-22</ArticleId><ArticleId IdType="pmc">PMC9430992</ArticleId><ArticleId IdType="pubmed">35770982</ArticleId></ArticleIdList></Reference><Reference><Citation>Conzentino M.S., Gonçalves A.C.A., Paula N.M., Rego F.G.M., Zanette D.L., Aoki M.N., Nardin J.M., Huergo L.F. A magnetic bead immunoassay to detect high affinity human IgG reactive to SARS-CoV-2 Spike S1 RBD produced in Escherichia coli. Braz. J. Microbiol. 2022;53:1263–1269. doi: 10.1007/s42770-022-00753-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42770-022-00753-x</ArticleId><ArticleId IdType="pmc">PMC9009495</ArticleId><ArticleId IdType="pubmed">35426068</ArticleId></ArticleIdList></Reference><Reference><Citation>Conzentino M.S., Santos T.P., Selim K.A., Wagner B., Alford J.T., Deobald N., Paula N.M., Rego F.G., Zanette D.L., Aoki M.N., et al. Ultra-fast, high throughput and inexpensive detection of SARS-CoV-2 seroconversion using Ni2+ magnetic beads. Anal. Biochem. 2021;631:114360. doi: 10.1016/j.ab.2021.114360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ab.2021.114360</ArticleId><ArticleId IdType="pmc">PMC8413102</ArticleId><ArticleId IdType="pubmed">34481802</ArticleId></ArticleIdList></Reference><Reference><Citation>Huergo L.F., Selim K.A., Conzentino M.S., Gerhardt E.C.M., Santos A.R.S., Wagner B., Alford J.T., Deobald N., Pedrosa F.O., de Souza E.M., et al. Magnetic Bead-Based Immunoassay Allows Rapid, Inexpensive, and Quantitative Detection of Human SARS-CoV-2 Antibodies. ACS Sens. 2021;3:703–708. doi: 10.1021/acssensors.0c02544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acssensors.0c02544</ArticleId><ArticleId IdType="pubmed">33496577</ArticleId></ArticleIdList></Reference><Reference><Citation>Conzentino M.S., Forchhammer K., Souza E.M., Pedrosa F.O., Nogueira M.B., Raboni S.M., Rego F.G.M., Zanette D.L., Aoki M.N., Nardin J.M., et al. Antigen production and development of an indirect ELISA based on the nucleocapsid protein to detect human SARS-CoV-2 seroconversion. Braz. J. Microbiol. 2021;52:2069–2073. doi: 10.1007/s42770-021-00556-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42770-021-00556-6</ArticleId><ArticleId IdType="pmc">PMC8329412</ArticleId><ArticleId IdType="pubmed">34342836</ArticleId></ArticleIdList></Reference><Reference><Citation>Bochnia-Bueno L., De Almeida S.M., Raboni S.M., Adamoski D., Amadeu L.L.M., Carstensen S., Nogueira M.B. Dynamic of humoral response to SARS-CoV-2 anti-Nucleocapsid and Spike proteins after CoronaVac vaccination. Diagn. Microbiol. Infect. Dis. 2022;102:115597. doi: 10.1016/j.diagmicrobio.2021.115597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diagmicrobio.2021.115597</ArticleId><ArticleId IdType="pmc">PMC8603270</ArticleId><ArticleId IdType="pubmed">34902621</ArticleId></ArticleIdList></Reference><Reference><Citation>Rambaut A., Holmes E.C., O’Toole Á., Hill V., McCrone J.T., Ruis C., du Plessis L., Pybus O.G. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat. Microbiol. 2020;5:1403–1407. doi: 10.1038/s41564-020-0770-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-0770-5</ArticleId><ArticleId IdType="pmc">PMC7610519</ArticleId><ArticleId IdType="pubmed">32669681</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J., Pouwels K.B., Stoesser N., Matthews P.C., Diamond I., Studley R., Rourke E., Cook D., Bell J.I., Newton J.N., et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nat. Med. 2022;28:1072–1082. doi: 10.1038/s41591-022-01721-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01721-6</ArticleId><ArticleId IdType="pmc">PMC9117148</ArticleId><ArticleId IdType="pubmed">35165453</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert P.B., Montefiori D.C., McDermott A.B., Fong Y., Benkeser D., Deng W., Zhou H., Houchens C.R., Martins K., Jayashankar L., et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375:43–50. doi: 10.1126/science.abm3425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm3425</ArticleId><ArticleId IdType="pmc">PMC9017870</ArticleId><ArticleId IdType="pubmed">34812653</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto S., Mizoue T., Ohmagari N. Analysis of Previous Infection, Vaccinations, and Anti-SARS-CoV-2 Antibody Titers and Protection Against Infection With the SARS-CoV-2 Omicron BA.5 Variant. JAMA Netw. Open. 2023;6:e233370. doi: 10.1001/jamanetworkopen.2023.3370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.3370</ArticleId><ArticleId IdType="pmc">PMC10020878</ArticleId><ArticleId IdType="pubmed">36929403</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray S.M., Ansari A.M., Frater J., Klenerman P., Dunachie S., Barnes E., Ogbe A. The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses. Nat. Rev. Immunol. 2023;23:304–316. doi: 10.1038/s41577-022-00809-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00809-x</ArticleId><ArticleId IdType="pmc">PMC9765363</ArticleId><ArticleId IdType="pubmed">36539527</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z.-R., Jiang Y.-W., Li F.-X., Liu D., Lin T.-F., Zhao Z.-Y., Wei C., Jin Q.-Y., Li X.-M., Jia Y.-X., et al. Efficacy of SARS-CoV-2 vaccines and the dose-response relationship with three major antibodies: A systematic review and meta-analysis of randomised controlled trials. Lancet Microbe. 2023;4:e236–e246. doi: 10.1016/S2666-5247(22)00390-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(22)00390-1</ArticleId><ArticleId IdType="pmc">PMC9974155</ArticleId><ArticleId IdType="pubmed">36868258</ArticleId></ArticleIdList></Reference><Reference><Citation>Buhre J.S., Pongracz T., Künsting I., Lixenfeld A.S., Wang W., Nouta J., Lehrian S., Schmelter F., Lunding H.B., Dühring L., et al. mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine. Front. Immunol. 2023;13:1020844. doi: 10.3389/fimmu.2022.1020844.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1020844</ArticleId><ArticleId IdType="pmc">PMC9877300</ArticleId><ArticleId IdType="pubmed">36713457</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C.Q., Vishwanath S., Carnell G.W., Chan A.C.Y., Heeney J.L. Immune imprinting and next-generation coronavirus vaccines. Nat. Microbiol. 2023;8:1971–1985. doi: 10.1038/s41564-023-01505-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-023-01505-9</ArticleId><ArticleId IdType="pubmed">37932355</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang H., Jung J., Ko G.Y., Lee J., Oh E.-J. Evaluation of Long-Term Adaptive Immune Responses Specific to SARS-CoV-2: Effect of Various Vaccination and Omicron Exposure. Vaccines. 2024;12:301. doi: 10.3390/vaccines12030301.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12030301</ArticleId><ArticleId IdType="pmc">PMC10974805</ArticleId><ArticleId IdType="pubmed">38543935</ArticleId></ArticleIdList></Reference><Reference><Citation>Goguet E., Olsen C.H., Meyer W.A., III, Ansari S., Powers J.H., III, Conner T.L., Coggins S.A., Wang W., Wang R., Illinik L., et al. Immune and behavioral correlates of protection against symptomatic post-vaccination SARS-CoV-2 infection. Front. Immunol. 2024;15:1287504. doi: 10.3389/fimmu.2024.1287504.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2024.1287504</ArticleId><ArticleId IdType="pmc">PMC10985347</ArticleId><ArticleId IdType="pubmed">38566991</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiteri G., D’agostini M., Abedini M., Ditano G., Collatuzzo G., Boffetta P., Vimercati L., Sansone E., De Palma G., Modenese A., et al. Protective role of SARS-CoV-2 anti-S IgG against breakthrough infections among European healthcare workers during pre and post-Omicron surge-ORCHESTRA project. Infection. 2024;52:1347–1356. doi: 10.1007/s15010-024-02189-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-024-02189-x</ArticleId><ArticleId IdType="pmc">PMC11289150</ArticleId><ArticleId IdType="pubmed">38326526</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia X., Cao S., Lee A.S., Manohar M., Sindher S.B., Ahuja N., Artandi M., Blish C.A., Blomkalns A.L., Chang I., et al. Anti-nucleocapsid antibody levels and pulmonary comorbid conditions are linked to post-COVID-19 syndrome. JCI Insight. 2022;7:e156713. doi: 10.1172/jci.insight.156713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.156713</ArticleId><ArticleId IdType="pmc">PMC9310538</ArticleId><ArticleId IdType="pubmed">35801588</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>